Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Medtronic
Mallinckrodt
Dow
Colorcon

Last Updated: June 28, 2022

CLINICAL TRIALS PROFILE FOR PADCEV


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for PADCEV

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03070990 ↗ A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Completed Seagen Inc. Phase 1 2017-04-24 The objective of this study is to assess the safety, tolerability and pharmacokinetics of enfortumab vedotin (ASG-22CE) when administered intravenously to Japanese subjects with locally advanced or metastatic urothelial carcinoma. This study will also assess the immunogenicity as defined by the incidence of anti-drug antibody (ADA) and anti-tumor activity of enfortumab vedotin (ASG-22CE) when administered intravenously to Japanese subjects with locally advanced or metastatic urothelial carcinoma.
NCT03070990 ↗ A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Completed Seattle Genetics, Inc. Phase 1 2017-04-24 The objective of this study is to assess the safety, tolerability and pharmacokinetics of enfortumab vedotin (ASG-22CE) when administered intravenously to Japanese subjects with locally advanced or metastatic urothelial carcinoma. This study will also assess the immunogenicity as defined by the incidence of anti-drug antibody (ADA) and anti-tumor activity of enfortumab vedotin (ASG-22CE) when administered intravenously to Japanese subjects with locally advanced or metastatic urothelial carcinoma.
NCT03070990 ↗ A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Completed Astellas Pharma Inc Phase 1 2017-04-24 The objective of this study is to assess the safety, tolerability and pharmacokinetics of enfortumab vedotin (ASG-22CE) when administered intravenously to Japanese subjects with locally advanced or metastatic urothelial carcinoma. This study will also assess the immunogenicity as defined by the incidence of anti-drug antibody (ADA) and anti-tumor activity of enfortumab vedotin (ASG-22CE) when administered intravenously to Japanese subjects with locally advanced or metastatic urothelial carcinoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PADCEV

Condition Name

Condition Name for PADCEV
Intervention Trials
Urothelial Cancer 5
Metastatic Urothelial Carcinoma 3
Urologic Neoplasms 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for PADCEV
Intervention Trials
Urinary Bladder Neoplasms 9
Carcinoma, Transitional Cell 7
Ureteral Neoplasms 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PADCEV

Trials by Country

Trials by Country for PADCEV
Location Trials
United States 176
Japan 34
France 25
Russian Federation 20
Spain 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for PADCEV
Location Trials
Texas 9
California 9
Pennsylvania 8
Ohio 8
New York 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PADCEV

Clinical Trial Phase

Clinical Trial Phase for PADCEV
Clinical Trial Phase Trials
Phase 3 5
Phase 2/Phase 3 1
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for PADCEV
Clinical Trial Phase Trials
Recruiting 10
Active, not recruiting 2
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PADCEV

Sponsor Name

Sponsor Name for PADCEV
Sponsor Trials
Seagen Inc. 7
Astellas Pharma Global Development, Inc. 5
Seattle Genetics, Inc. 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for PADCEV
Sponsor Trials
Industry 30
Other 2
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Express Scripts
McKinsey
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.